Recent clinical advancements suggest that biological drugs for Sjögren disease could transform the management of salivary dysfunction. Sjögren disease often causes systemic complications, with dry mouth being a hallmark symptom. Researchers are now evaluating how novel biological agents target the underlying pathophysiology of this condition. Consequently, these therapies may offer new hope for patients struggling with persistent hyposalivation.

The Role of Biological Drugs for Sjögren in Salivary Flow

A systematic review analyzed fourteen randomized clinical trials involving 1,772 patients to assess therapeutic efficacy. The studies focused on various agents, including rituximab, iscalimab, and human interferon (IFN)-α. Specifically, four trials reported that rituximab and iscalimab led to a significant increase in unstimulated whole salivary flow. Furthermore, participants experienced a noticeable improvement in dry mouth sensations. These findings indicate that these agents may restore glandular activity more effectively than traditional palliative care. However, other biologicals like infliximab and tocilizumab did not demonstrate similar benefits in this review. Most patients tolerated the treatments well, with the researchers observing no relevant adverse effects across the included studies.

Clinical Implications and Future Directions

The potential benefits of these therapies highlight a shifting landscape in autoimmune treatment. Moreover, the integration of biological drugs into clinical practice requires careful patient selection. While rituximab and iscalimab show promise, larger and more standardized trials are still necessary. This will help doctors determine the optimal timing and dosage for these interventions. Currently, these drugs provide a valuable alternative when standard secretagogues fail to provide relief. Additionally, clinicians should remain updated on emerging data regarding long-term safety and efficacy profiles.

Frequently Asked Questions

Which biological drugs are most effective for dry mouth in Sjögren disease?

Research indicates that rituximab, iscalimab, and human interferon-α are among the most promising biological agents for improving salivary flow and reducing xerostomia symptoms.

What are the common side effects of biological treatments for Sjögren?

The recent systematic review observed no relevant adverse effects in the clinical trials studied, suggesting that these agents are generally well-tolerated by patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always consult with a qualified healthcare professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Seoane-Romero JM et al. Effectiveness of biological drugs in the treatment of xerostomia and salivary hypofunction in patients with Sjögren disease. J Am Dent Assoc. 2026 Mar 10. doi: undefined. PMID: 41805268.

Pijpe J, Vissink A, Kallenberg CG. The Future of Biologic Agents in the Treatment of Sjögren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):519-533. doi: 10.1016/j.rdc.2016.03.010.

Grader-Beck T. Novel Biologic for Sjogren's Clears Penultimate Hurdle. MedPage Today. October 30, 2025.